The PDF was saved in your download folder or opened in a new tab in your browser. You can find the download folder on your drive or in the browser bar of Firefox and Safari at the top right next to the arrow icon.
We have all learned: “Common things are common, except when the diagnosis is rare.” So far so good. Thanks to the large number of cases with increasingly networked data and by taking the current WHO classification as a basis, it is possible for even rare diagnoses to be assigned with greater precision today. This becomes more difficult, however, if the individual findings of the diagnostics chain and the blood values do not fit together in a conclusive way – or if any uncertainty simply remains even though the patient is definitely clinically ill. So what is the next step?
MLLSEQ is the name of the sequencing service and the affiliate company of MLL Munich Leukemia Laboratory that was relaunched around five months ago. With the slogan, “We are the next generation – Sequencing Service,” MLLSEQ is offering its extensive next generation sequencing (NGS) knowledge – from library preparation to sequencing only – along with detailed bioinformatic processing and visualization of the data generated. But why the change from MLL Dx to MLLSEQ? What has changed since the reorientation of the label? And how exactly are the sequencing processes at MLLSEQ run? So, it’s high time for a talk with Dr. rer. nat. Manja Meggendorfer.
Every day, the MLL team focuses its combined efforts on making it possible for patients around the world to receive the best therapy thanks to quick and targeted leukemia diagnostics. But how does a normal workday look for the 200 or so employees? What are the different departments and areas? Our new magazine series “Introducing MLL” will be offering you a glimpse into our laboratory. In the first part, we want to present our Sample Receipt area.
The Munich Leukemia Laboratory and the newly founded Institute of AI for Health (AIH) of the Helmholtz Center of Munich have agreed on comprehensive collaboration for research and development. The primary goal is the implementation of machine learning and artificial intelligence in various areas of leukemia diagnostics.